Participation in cancer treatment clinical trials is a key measure for delivery of quality cancer care, yet adult trial participation in the U.S. remains under 3%, with even lower participation rates among ethnic and racial minorities and people over 65. Whether focusing on studies sponsored by the National Cancer Institute or industry, institutions often struggle in isolation to achieve efficient and effective accrual.
The Commission on Cancer’s 2015 guidelines dictate higher accrual rates for all cancer treating institutions, so it is more important than ever to use effective accrual practices that are grounded in evidence. Unfortunately, there are few evidence-based practices to help sites achieve higher accrual rates. ENACCT is creating this evidence through its leadership of the Cancer Clinical Trial Collaborative Learning Network (CCTCLN). The CCTCLN is built upon the successful work of the National Pilot Collaborative completed in 2012. (Read more here). The goal of the CCTCLN is to further the goal of the Pilot: to identify practical, patient-centered approaches to increase accrual overall and, in particular, for ethnic /racial minorities and people over 65.
ENACCT is now accepting applications for the next generation of this network to assist cancer centers and community oncology practices in becoming more effective and efficient in their approaches to recruitment, accrual and retention. (See www.enacct.org for more details.). The Learning Network Can Help Cancer Centers and Community Oncology Practices by:
Institutions who join this Network will participate in a unique opportunity for improving their accrual practices in a cost-effective manner. Applications are open now and are due June 21 2013. (See www.enacct.org for more details.)
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.